While the exercise to increase the availability of the vaccine is rapid, the investigation of the transition of the corona and the effect of the vaccine on its new variants has also started. Scientists at the ICMR and CSIR are trying to find out how well the Covaxin and Covishield used in India are working towards the new variants of the Corona.

Responsible for British, South African, and double mutation variants

Three British, South African, and double mutation variants are being blamed for the second wave of Corona in India. Asked about the potential for the existing vaccine to be less effective on the new variant of Corona, Anurag Aggarwal, director of the Institute of Genomics and Integrative Biology under CSIR, said that the effect of covishield and covaxin is being studied on the new variant of Corona is. Only after his report comes can something be clearly said in this regard.

For the first time in the world, so many vaccines were ready in less than eight months

At the same time, ICMR scientists do not consider the new variant of Corona and the Efficacy of the vaccine to be a big issue. A senior scientist at the ICMR said that for the first time in the world, it has helped to produce so many vaccines in less than eight months. According to him, once a vaccine is prepared on any platform and its safety and effectiveness are proven, it can be easily tailored to the new variant. He said that mutation in viruses is a normal process and one should always be prepared to deal with it. He gave the example of the influenza virus which completely changes every year and every year a new vaccine has to be made for it. But it is not difficult to develop a new vaccine on the same platform.

Covishield found to be fully functional

It is worth noting that till now only the British variant has been studied in India regarding Covishield's Efficiency. In which Covishield was found to be fully effective. But the vaccine affixation on South African and Brazilian variants has not yet been studied in India. At the same time, there has been no study on the effectiveness of any variant regarding covaxin. While the effectiveness of a vaccine on the double mutant variant has not been studied. The study in several countries found the Covishield to be less effective on the South African and Brazilian variants. For this reason, South Africa returned half a million doses of Covishield to the Serum Institute.